The DOI matches its Crossref record.
Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)
Abstract
OBJECTIVES: Cirrhotics with minimal hepatic encephalopathy (MHE) have a poor health-related quality of life (HRQOL). Treatment of MHE is still evolving. The aim of this double-blind randomized pilot study was to assess the efficacy of rifaximin in improving neuropsychometric (NP) test performance and HRQOL in patients with MHE. METHODS: MHE was diagnosed if any two NP tests (number and figure connection tests, picture completion, digit symbol, and block design tests) were deranged beyond 2 s.d. of normal. HRQOL was assessed using the sickness impact profile (SIP) questionnaire. RESULTS: A total of 486 patients with cirrhosis were screened and 284 were found eligible. Out of these 115 (40.9%) had MHE, of which 21 refused consent and 94 were randomized to receive placebo (n=45) and rifaximin (n=49; 1200 mg/day) for 8 weeks. At the end of treatment, significantly more number of patients in rifaximin group showed reversal of MHE (75.5% (37/49) vs. 20% (9/45) in placebo group; P<0.0001). Rifaximin group also showed significant reduction in mean number of abnormal NP tests (baseline, 2.35 (95% confidence interval (CI), 2.17-2.53); 2 weeks, 1.29 (95% CI, 1.02-1.56), P=0.002; 8 weeks, 0.81 (95% CI, 0.61-1.02), P=0.000), compared with placebo group (baseline, 2.31 (95% CI, 2.03-2.59); 2 weeks, 2.03 (95% CI, 1.74-2.31); 8 weeks, 1.97 (95% CI, 1.69-2.25), P>0.05). The mean total SIP score also improved significantly in rifaximin group (baseline, 11.67 (95% CI, 10.31-13.03); 8 weeks, 6.45 (95% CI, 5.59-7.30); P=0.000) compared with placebo group (baseline, 9.86 (95% CI, 8.66-11.06); 8 weeks, 8.51 (95% CI, 7.35-9.67); P=0.82). Improvement in HRQOL correlated with improvement in NP tests. Rifaximin was well tolerated. CONCLUSIONS: Rifaximin significantly improves both cognitive functions and HRQOL in patients with MHE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014) · Hepatology · doi:10.1002/hep.27210 · Cited by 2,056
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
“The use of rifaximin for MHE therapy is an attractive proposition due to its efficacy, tolerability and gut-specific action [4,5,7].”
BackgroundEvidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 422
Alzheimer’s disease and gut microbiota
Hu, X., Wang, T., & Jin, F. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5083-9 · Cited by 371
Bellot, P., Francés, R., & Such, J. (2013) · Liver International · doi:10.1111/liv.12021 · Cited by 254
Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy
Kimer, N., Krag, A., Møller, S., Bendtsen, F., & Gluud, L. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12803 · Cited by 203
The gut microbiota and the liver. Pathophysiological and clinical implications
Quigley, E. M. M., Stanton, C., & Murphy, E. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.023 · Cited by 133
Antibiotics for the treatment of hepatic encephalopathy
Patidar, K. R., & Bajaj, J. S. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9383-5 · Cited by 110
Ahluwalia, V., Wade, J. B., Heuman, D. M., Hammeke, T. A., Sanyal, A. J., Sterling, R. K., Stravitz, R. T., Luketic, V., Siddiqui, M. S., Puri, P., et al. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9507-6 · Cited by 92
Bajaj, J. S., Thacker, L. R., Wade, J. B., Sanyal, A. J., Heuman, D. M., Sterling, R. K., Gibson, D. P., Stravitz, R. T., Puri, P., Fuchs, M., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04842.x · Cited by 83
Markers of bacterial translocation in end-stage liver disease
Koutsounas, I. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i20.2264 · Cited by 55
Complications, symptoms, quality of life and pregnancy in cholestatic liver disease
Zakharia, K., Tabibian, A., Lindor, K. D., & Tabibian, J. H. (2018) · Liver International · doi:10.1111/liv.13591 · Cited by 42
Hepatic Encephalopathy Involves Interactions Among the Microbiota, Gut, Brain
Victor, D. W., & Quigley, E. M. M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.022 · Cited by 12
Metadata
- Authors
- Sidhu, S. S., Goyal, O., Mishra, B. P., Sood, A., Chhina, R. S., & Soni, R. K.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-02
- Volume
- 106
- Issue
- 2
- Pages
- 307-316
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2062554669
- Cited by
- 245
- References
- 0
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.